NDA 210807 · Msd Merck CO
Delstrigo
Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate · Oral · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 30, 2018
Approved uses
4
Original approval plus efficacy supplements
Registered trials
66
23 Phase 3, 9 recruiting
FAERS reports
313
259 serious, 24 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in people with concomitant HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DELSTRIGO. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.2) ] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B (HBV) have been reported in people with concomitant HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), two of the components...
What it is approved for
From the label in effect Jul 8, 2026.
DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14) ] . DELSTRIGO is a three-drug combination of doravirine (a non-nucleoside reverse transcriptase inhibitor [NNRTI]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside analogue reverse transcriptase inhibitors) and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO. ( 1 )
Mechanism: DELSTRIGO is a fixed-dose combination of the antiretroviral drugs doravirine, lamivudine, and TDF [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 27, 2022 Supplement 8 · Efficacy · priority review LabelLetter
- Oct 10, 2019 Supplement 3 · Efficacy LetterLabel
- Sep 19, 2019 Supplement 2 · Efficacy LetterLabel
- Aug 30, 2018 Original approval · Type 4 - New Combination LetterLabelReview
1 products under this application
- DELSTRIGO · DORAVIRINE 100MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Doravirine" as an intervention, any sponsor and status, largest first.
- Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04776252 · 2,000 participants (planned) · Start Sep 15, 2021 · Primary completion May 29, 2029
Drug: MK-8591A · For: HIV-1 Infection
Sites: Phoenix, Arizona; Sacramento, California; Washington D.C., District of Columbia · 93 sites in all
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02275780 · 769 participants · Start Dec 1, 2014 · Primary completion Sep 29, 2016
Drug: Doravirine; Darunavir and 2 more · For: HIV-1
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02403674 · 734 participants · Start Jun 5, 2015 · Primary completion Mar 20, 2017
Drug: Doravirine, Tenofovir, Lamivudine; ATRIPLA™ and 1 more · For: Human Immunodeficiency Virus (HIV)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02397096 · 673 participants · Start Jun 9, 2015 · Primary completion Feb 22, 2018
Drug: Doravirine, Tenofovir, Lamivudine; Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor and 3 more · For: HIV-1 Infection
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04223778 · 672 participants · Start Feb 18, 2020 · Primary completion Sep 8, 2021
Drug: DOR/ISL; ART · For: HIV Infection
Sites: Washington D.C., District of Columbia; Ft. Pierce, Florida; Orlando, Florida · 78 sites in all
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04223791 · 643 participants · Start Feb 18, 2020 · Primary completion Aug 26, 2021
Drug: DOR/ISL; BIC/FTC/TAF and 2 more · For: HIV Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 89 sites in all
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05766501 · 641 participants · Start Mar 17, 2023 · Primary completion Oct 16, 2025
Drug: DOR/ISL · For: HIV Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death20
- nausea20
- weight increased18
- pain17
- anxiety14
- fatigue13
- no adverse event13
- pathogen resistance13
- depression12
- headache12
- product dose omission issue12
- diarrhoea11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2019 | 6 |
| 2020 | 25 |
| 2021 | 33 |
| 2022 | 32 |
| 2023 | 67 |
| 2024 | 64 |
| 2025 | 54 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Delstrigo (Doravirine/Lamivu/Tenofov Diso)
2024 spending
$18.5M
Beneficiaries
796
6,688 claims
Per beneficiary
$23,220
$88.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,865,683 |
| 2021 | $8,118,273 |
| 2022 | $11,982,556 |
| 2023 | $16,119,607 |
| 2024 | $18,483,115 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
Orkin C, Mngqibisa R, Velez JD, et al. · Lancet 2026 · Clinical Trial, Phase III, Multicenter Study
- Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.
Rockstroh JK, Paredes R, Cahn P, et al. · Clin Infect Dis 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.
Woods J, Lebina L, Möller K, et al. · JAMA 2026 · Clinical Trial, Phase III, Equivalence Trial
- Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
Colson AE, Mills AM, Ramgopal MN, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, et al. · Lancet HIV 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.
Carr A, Mngqibisa R, Khaertynova I, et al. · AIDS 2026 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.